U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again under the new VBP system.